Q-omics provides the consensus-scored ASB5 profile across patient tissues and cancer cell-line models. ASB5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ASB5 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ASB5 RNA expression shows 11,298 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where ASB5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASB5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASB5 survival associations across molecular data types. ASB5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASB5 RNA expression–survival associations across cancer types. High ASB5 expression shows unfavorable associations in HNSC, SKCM, LGG, UVM, KIRC and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ASB5 RNA expression.
This table summarizes ASB5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ASB5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASB5 shows lower tumor expression in KIRC, BLCA, KIRP, COAD, LUSC and STAD. The KIRC box plot shows higher ASB5 RNA expression in normal versus tumor tissue (log2 FC = −0.674, t-test p < 0.001).
This table shows molecular features associated with ASB5 in patient tissues and cancer cell lines. In patient samples, ASB5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ASB5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
